A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

OBJECTIVES. This study aimed to evaluate the efficacy and safety of once-per-cycle balugrastim versus pegfilgrastim for neutrophil support in breast cancer patients receiving myelosuppressive chemotherapy. METHODS. Breast cancer patients (n = 256) were randomized to 40 or 50 mg of subcutaneous balug...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Gladkov, Oleg, Moiseyenko, Vladimir, Bondarenko, Igor N., Shparyk, Yaroslav, Barash, Steve, Adar, Liat, Avisar, Noa
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2016
Témata:
Academia-Pharma Intersect:Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4709202/
https://ncbi.nlm.nih.gov/pubmed/26668251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0152
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky